Tethys makes its prediabetes PreDx test available with finger stick collection method.
M2 PHARMA-May 29, 2013-Tethys makes its prediabetes PreDx test available with finger stick collection method(C)2013 M2 COMMUNICATIONS
29 May 2013 - US cardiometabolic diagnostics company Tethys Bioscience said on Tuesday it had expanded the access to its prediabetes multi-biomarker blood test PreDx with the addition of testing using capillary blood collected via a finger stick procedure.
The company's senior VP of research and development Dr Ted Tarasow said that the company is expanding access to the PreDx test from the 25% of clinicians with in-office phlebotomy to the 88% of primary care practices that routinely carry out finger stick tests.
The PreDx test gauges seven biomarkers implicated in the development of Type 2 diabetes, and uses a proprietary algorithm to generate a "personalised" numerical score that ranks a prediabetic's five-year risk of progression to diabetes on a scale of 1 to 10, with a higher score signalling a higher five-year risk of progression.
Baseline scores are used to stratify prediabetes patients into low, moderate or high- risk categories for disease progression, then retesting is used to monitor changes in the patient's score, which reflect the efficacy of preventive interventions in reducing the patient's level of risk.
((Comments on this story may be sent to firstname.lastname@example.org))
|Printer friendly Cite/link Email Feedback|
|Date:||May 29, 2013|
|Previous Article:||i"?Fresenius Kabi USA recalls Magnesium Sulphate Injection.|
|Next Article:||Luminex, Merck KGaA's EMD Millipore renew supply, distribution deal.|